KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.

Anca Streinu-Cercel, Antonella Castagna, Shan-Chwen Chang, Yao-Shen Chen, Yiannis Koullias, Afsaneh Mozaffarian, Robert H Hyland, Rita Humeniuk, Luzelena Caro, Santosh Davies, Lauren Rodriguez, Charlotte Hedskog, Shuguang Chen, Kim Etchevers, Nicole Behenna-Renton, Joe Llewellyn, Anu Osinusi, Frank Duff, Alejandro Barrat Hernández, Damien McNally, Jesus Abraham Simon-Campos, Fabio Eudes Leal, Leon F Fouche, Juan Maria González Del Castillo

Clin Infect Dis 82(1) e24-e32

PMID40694627
PMCID-
DOI10.1093/cid/ciaf406
发表日期2025-07-22
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Obeldesivir is an oral nucleoside analog prodrug inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: Nonhospitalized adults with risk factors for developing severe coronavirus disease 2019 (COVID-19) were enrolled ≤5 days from COVID-19 symptom onset and randomized 1:1 to receive obeldesivir 350 mg or placebo twice daily for 5 days. The primary end point was COVID-19-related hospitalization or all-cause death by day 29. Other end points included time to symptom alleviation by day 15, change in SARS-CoV-2 viral RNA copy number and infectious viral titer, and incidence of adverse events and laboratory abnormalities. RESULTS: Four hundred and sixty five participants were randomized and received ≥1 dose of study drug. Baseline characteristics were generally balanced between groups. Overall, 58% had received ≥1 COVID-19 vaccination, and 92% were seropositive for SARS-CoV-2 antibodies. COVID-19-related hospitalization or all-cause death by day 29 was reported in 0 of 211 (0%) participants with obeldesivir and 1 of 207 (0.5%) participants with placebo (log-rank P = .32). Time to COVID-19 symptom alleviation was numerically shorter with obeldesivir versus placebo. Obeldesivir reduced viral RNA copy number at day 5 and infectious titer at days 3 and 5 versus placebo. The safety profile was generally comparable across arms. CONCLUSIONS: Although underpowered in the context of a changing COVID-19 landscape, obeldesivir in nonhospitalized adults with targeted risk factors did not improve COVID-19-related hospitalization or all-cause death. Obeldesivir reduced viral RNA copy number and infectious titer, demonstrating its ability to inhibit SARS-CoV-2 replication, and resulted in numerically faster symptom alleviation. CLINICAL TRIALS REGISTRATION: NCT05603143; EudraCT 2022-002741-18.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。